Profiling HPV-16–specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients
Journal of Experimental Medicine, 2020•rupress.org
Cellular immunotherapeutics targeting the human papillomavirus (HPV)–16 E6 and E7
proteins have achieved limited success in HPV-positive oropharyngeal cancer (OPC). Here
we have conducted proteome-wide profiling of HPV-16–specific T cell responses in a cohort
of 66 patients with HPV-associated OPC and 22 healthy individuals. Unexpectedly, HPV-
specific T cell responses from OPC patients were not constrained to the E6 and E7 antigens;
they also recognized E1, E2, E4, E5, and L1 proteins as dominant targets for virus-specific …
proteins have achieved limited success in HPV-positive oropharyngeal cancer (OPC). Here
we have conducted proteome-wide profiling of HPV-16–specific T cell responses in a cohort
of 66 patients with HPV-associated OPC and 22 healthy individuals. Unexpectedly, HPV-
specific T cell responses from OPC patients were not constrained to the E6 and E7 antigens;
they also recognized E1, E2, E4, E5, and L1 proteins as dominant targets for virus-specific …
Cellular immunotherapeutics targeting the human papillomavirus (HPV)–16 E6 and E7 proteins have achieved limited success in HPV-positive oropharyngeal cancer (OPC). Here we have conducted proteome-wide profiling of HPV-16–specific T cell responses in a cohort of 66 patients with HPV-associated OPC and 22 healthy individuals. Unexpectedly, HPV-specific T cell responses from OPC patients were not constrained to the E6 and E7 antigens; they also recognized E1, E2, E4, E5, and L1 proteins as dominant targets for virus-specific CD8+ and CD4+ T cells. Multivariate analysis incorporating tumor staging, treatment status, and smoking history revealed that treatment status had the most significant impact on HPV-specific CD8+ and CD4+ T cell immunity. Specifically, the breadth and overall strength of HPV-specific T cell responses were significantly higher before the commencement of curative therapy than after therapy. These data provide the first glimpse of the overall human T cell response to HPV in a clinical setting and offer groundbreaking insight into future development of cellular immunotherapies for HPV-associated OPC patients.
rupress.org